News

Fierce Pharma16h
Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch
Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...
MarketWatch21h
S&P 500 Index
Gilead Sciences Inc. $101.80-4.35-4.10% ...